A MYOCARDIALIS INFARKTUS LABORATORIUMI MARKEREI

Translated title of the contribution: Laboratory diagnostic tests of the acute myocardial infarct

J. Marki-Zay, E. Nagy, L. Dux

Research output: Contribution to journalArticle

Abstract

The elevation and the consecutive decrease of myocardial marker enzymes and proteins seems to have a predominant role among WHO recommended diagnostic criteria of AMI, since the other two symptoms, EKG signals and chest pain are missing or atypical quite often. The elevation of an ideal cardiac muscle specific biochemical AMI marker follows the tissue damage in the blood plasma soon, and its prolonged presence allows late diagnosis as well as the followup of the process. Proper application and evaluation of the success of thrombolytic therapy requires the fast decrease of the elevated biochemical markers in the bloodstream as well. Availability of technically simple and fast testing methods, even bedside tests are further challenges for biochemical AMI markers. Myoglobin can be recommended for early detection and for the control of thrombolytic therapy due to its biochemical and pathobiochemical features. For the complete follow-up CK-MB mass determination and the inhibitory Troponin I subunit seems be the markers of choice nowadays.

Original languageHungarian
Pages (from-to)596-605
Number of pages10
JournalLege Artis Medicinae
Volume8
Issue number9
Publication statusPublished - 1998

Fingerprint

Routine Diagnostic Tests
Biomarkers
Thrombolytic Therapy
Myocardial Infarction
Troponin I
Myoglobin
Delayed Diagnosis
Chest Pain
Myocardium
Electrocardiography
Enzymes
Proteins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A MYOCARDIALIS INFARKTUS LABORATORIUMI MARKEREI. / Marki-Zay, J.; Nagy, E.; Dux, L.

In: Lege Artis Medicinae, Vol. 8, No. 9, 1998, p. 596-605.

Research output: Contribution to journalArticle

Marki-Zay, J, Nagy, E & Dux, L 1998, 'A MYOCARDIALIS INFARKTUS LABORATORIUMI MARKEREI', Lege Artis Medicinae, vol. 8, no. 9, pp. 596-605.
Marki-Zay, J. ; Nagy, E. ; Dux, L. / A MYOCARDIALIS INFARKTUS LABORATORIUMI MARKEREI. In: Lege Artis Medicinae. 1998 ; Vol. 8, No. 9. pp. 596-605.
@article{623fe450e4854316b4d1834f32e05455,
title = "A MYOCARDIALIS INFARKTUS LABORATORIUMI MARKEREI",
abstract = "The elevation and the consecutive decrease of myocardial marker enzymes and proteins seems to have a predominant role among WHO recommended diagnostic criteria of AMI, since the other two symptoms, EKG signals and chest pain are missing or atypical quite often. The elevation of an ideal cardiac muscle specific biochemical AMI marker follows the tissue damage in the blood plasma soon, and its prolonged presence allows late diagnosis as well as the followup of the process. Proper application and evaluation of the success of thrombolytic therapy requires the fast decrease of the elevated biochemical markers in the bloodstream as well. Availability of technically simple and fast testing methods, even bedside tests are further challenges for biochemical AMI markers. Myoglobin can be recommended for early detection and for the control of thrombolytic therapy due to its biochemical and pathobiochemical features. For the complete follow-up CK-MB mass determination and the inhibitory Troponin I subunit seems be the markers of choice nowadays.",
keywords = "Acute myocardial infarct, Creatine kinase, Creatine kinase MB isoform, Myoglobin, Troponin I, Troponin T",
author = "J. Marki-Zay and E. Nagy and L. Dux",
year = "1998",
language = "Hungarian",
volume = "8",
pages = "596--605",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "9",

}

TY - JOUR

T1 - A MYOCARDIALIS INFARKTUS LABORATORIUMI MARKEREI

AU - Marki-Zay, J.

AU - Nagy, E.

AU - Dux, L.

PY - 1998

Y1 - 1998

N2 - The elevation and the consecutive decrease of myocardial marker enzymes and proteins seems to have a predominant role among WHO recommended diagnostic criteria of AMI, since the other two symptoms, EKG signals and chest pain are missing or atypical quite often. The elevation of an ideal cardiac muscle specific biochemical AMI marker follows the tissue damage in the blood plasma soon, and its prolonged presence allows late diagnosis as well as the followup of the process. Proper application and evaluation of the success of thrombolytic therapy requires the fast decrease of the elevated biochemical markers in the bloodstream as well. Availability of technically simple and fast testing methods, even bedside tests are further challenges for biochemical AMI markers. Myoglobin can be recommended for early detection and for the control of thrombolytic therapy due to its biochemical and pathobiochemical features. For the complete follow-up CK-MB mass determination and the inhibitory Troponin I subunit seems be the markers of choice nowadays.

AB - The elevation and the consecutive decrease of myocardial marker enzymes and proteins seems to have a predominant role among WHO recommended diagnostic criteria of AMI, since the other two symptoms, EKG signals and chest pain are missing or atypical quite often. The elevation of an ideal cardiac muscle specific biochemical AMI marker follows the tissue damage in the blood plasma soon, and its prolonged presence allows late diagnosis as well as the followup of the process. Proper application and evaluation of the success of thrombolytic therapy requires the fast decrease of the elevated biochemical markers in the bloodstream as well. Availability of technically simple and fast testing methods, even bedside tests are further challenges for biochemical AMI markers. Myoglobin can be recommended for early detection and for the control of thrombolytic therapy due to its biochemical and pathobiochemical features. For the complete follow-up CK-MB mass determination and the inhibitory Troponin I subunit seems be the markers of choice nowadays.

KW - Acute myocardial infarct

KW - Creatine kinase

KW - Creatine kinase MB isoform

KW - Myoglobin

KW - Troponin I

KW - Troponin T

UR - http://www.scopus.com/inward/record.url?scp=0031714610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031714610&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 596

EP - 605

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 9

ER -